Literature DB >> 19168524

Indication for bromocriptine in peripartum cardiomyopathy.

Frederic Mouquet, Nicolas Lamblin, Pascal de Groote.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19168524      PMCID： PMC2639412          DOI： 10.1093/eurjhf/hfn038

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN： 1388-9842            Impact factor:   15.534


× No keyword cloud information.
  5 in total

1.  Caution in the use of bromocriptine in peripartum cardiomyopathy.

Authors:  James D Fett
Journal:  J Am Coll Cardiol       Date:  2008-05-27       Impact factor: 24.094

Review 2.  Peripartum cardiomyopathy.

Authors:  Karen Sliwa; James Fett; Uri Elkayam
Journal:  Lancet       Date:  2006-08-19       Impact factor: 79.321

3.  A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy.

Authors:  Denise Hilfiker-Kleiner; Karol Kaminski; Edith Podewski; Tomasz Bonda; Arnd Schaefer; Karen Sliwa; Olaf Forster; Anja Quint; Ulf Landmesser; Carola Doerries; Maren Luchtefeld; Valeria Poli; Michael D Schneider; Jean-Luc Balligand; Fanny Desjardins; Aftab Ansari; Ingrid Struman; Ngoc Q N Nguyen; Nils H Zschemisch; Gunnar Klein; Gerd Heusch; Rainer Schulz; Andres Hilfiker; Helmut Drexler
Journal:  Cell       Date:  2007-02-09       Impact factor: 41.582

4.  Recovery from peripartum cardiomyopathy after treatment with bromocriptine.

Authors:  Dirk Habedank; York Kühnle; Thomas Elgeti; Joachim W Dudenhausen; Wilhelm Haverkamp; Rainer Dietz
Journal:  Eur J Heart Fail       Date:  2008-10-15       Impact factor: 15.534

5.  Characterisation of peripartum cardiomyopathy by cardiac magnetic resonance imaging.

Authors:  Frederic Mouquet; Christophe Lions; Pascal de Groote; Nadia Bouabdallaoui; Serge Willoteaux; Joel Dagorn; Philippe Deruelle; Nicolas Lamblin; Christophe Bauters; Jean Paul Beregi
Journal:  Eur Radiol       Date:  2008-07-19       Impact factor: 5.315
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.